BACKGROUND: Ondansetron is increasingly used to prevent emesis in children with acute gastroenteritis; however, the optimal dose is unknown. OBJECTIVE: To determine if higher doses of oral ondansetron are associated with greater efficacy or side effects. METHODS: We analyzed data from a prospective clinical trial performed between January 2004 and April 2005. Data were collected on 105 children with dehydration due to gastroenteritis who received an ondansetron oral disintegrating formulation. The following outcomes of efficacy were analyzed: number of vomiting episodes, volume of oral rehydration fluids consumed, percent weight gain, and the proportions of children who had ongoing vomiting, received intravenous rehydration, and were hospitalized. In addition, the number of episodes of diarrhea was evaluated to measure whether there were dose-dependent side effects. RESULTS: Participants were aged 0.5-8.2 years and the dose ranged between 0.13 and 0.26 mg/kg. There was no significant association between the dose of ondansetron and the outcomes of number of vomiting episodes, volume of fluids consumed, increase in bodyweight, or number of diarrhea episodes/hour. The mean dose of ondansetron (mg/kg) administered was not different amongst those who did and did not have ongoing vomiting, undergo hospitalization, and receive intravenous rehydration. CONCLUSIONS: Within the dose range of 0.13-0.26 mg/kg, higher doses of ondansetron were not superior to lower doses, nor were they associated with increased side effects. Thus, ondansetron in this dose range was shown to result in a similar reduction in emesis in children with acute gastroenteritis.
BACKGROUND:Ondansetron is increasingly used to prevent emesis in children with acute gastroenteritis; however, the optimal dose is unknown. OBJECTIVE: To determine if higher doses of oral ondansetron are associated with greater efficacy or side effects. METHODS: We analyzed data from a prospective clinical trial performed between January 2004 and April 2005. Data were collected on 105 children with dehydration due to gastroenteritis who received an ondansetron oral disintegrating formulation. The following outcomes of efficacy were analyzed: number of vomiting episodes, volume of oral rehydration fluids consumed, percent weight gain, and the proportions of children who had ongoing vomiting, received intravenous rehydration, and were hospitalized. In addition, the number of episodes of diarrhea was evaluated to measure whether there were dose-dependent side effects. RESULTS:Participants were aged 0.5-8.2 years and the dose ranged between 0.13 and 0.26 mg/kg. There was no significant association between the dose of ondansetron and the outcomes of number of vomiting episodes, volume of fluids consumed, increase in bodyweight, or number of diarrhea episodes/hour. The mean dose of ondansetron (mg/kg) administered was not different amongst those who did and did not have ongoing vomiting, undergo hospitalization, and receive intravenous rehydration. CONCLUSIONS: Within the dose range of 0.13-0.26 mg/kg, higher doses of ondansetron were not superior to lower doses, nor were they associated with increased side effects. Thus, ondansetron in this dose range was shown to result in a similar reduction in emesis in children with acute gastroenteritis.
Authors: L X Cubeddu; L M Trujillo; I Talmaciu; V Gonzalez; J Guariguata; J Seijas; I A Miller; W Paska Journal: Aliment Pharmacol Ther Date: 1997-02 Impact factor: 8.171
Authors: Christine M Stork; Kathleen M Brown; Tracey H Reilly; LaLaina Secreti; Lawrence H Brown Journal: Acad Emerg Med Date: 2006-08-10 Impact factor: 3.451
Authors: Susann B Hasler; Andreas Hirt; Annette Ridolfi Luethy; Kurt K Leibundgut; Roland A Ammann Journal: Support Care Cancer Date: 2007-10-17 Impact factor: 3.603
Authors: T Christopher Mast; Carla DeMuro-Mercon; Claudia M Kelly; Leigh Ellen Floyd; Emmanuel B Walter Journal: BMC Pediatr Date: 2009-02-06 Impact factor: 2.125
Authors: C Seynaeve; J Schuller; K Buser; H Porteder; S Van Belle; P Sevelda; D Christmann; M Schmidt; H Kitchener; D Paes Journal: Br J Cancer Date: 1992-07 Impact factor: 7.640
Authors: Stephen B Freedman; Sajid B Soofi; Andrew R Willan; Sarah Williamson-Urquhart; Noshad Ali; Jianling Xie; Fady Dawoud; Zulfiqar A Bhutta Journal: Ann Emerg Med Date: 2018-11-02 Impact factor: 5.721
Authors: Mark P Simons; Brian L Pike; Christine E Hulseberg; Michael G Prouty; Brett E Swierczewski Journal: Trop Dis Travel Med Vaccines Date: 2016-01-12
Authors: Stephen B Freedman; Sarah Williamson-Urquhart; Anna Heath; Petros Pechlivanoglou; Gareth Hopkin; Serge Gouin; Amy C Plint; Andrew Dixon; Darcy Beer; Gary Joubert; Christopher McCabe; Yaron Finkelstein; Terry P Klassen Journal: Trials Date: 2020-05-27 Impact factor: 2.279